The immunosuppressive effects of the dunaimycins, a new complex of spiroketal 24-membered macrolides, were comparedto cyclosporin A, ascomycin, and rapamycin. Each dunaimycin was a potent inhibitor of the mitogenic response observed in mixed murine splenocyte or humanleukocyte cultures, and like immunosuppressive drugs these compounds were relatively less potent inhibitors of the constitutive proliferation of murine EL4 thymoma cells. Dunaimycin D4Sshowed no selectivity in inhibiting the mitogenic response of spleen cells to concanavalin A, pokeweed mitogen, lipopolysaccharide, or phytohemagglutinin. Cyclosporin A and ascomycin did not inhibit interleukin 2 dependent proliferation, whereas the dunaimycins and rapamycin blocked the uptake of
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Cyclosporin A is an effective immunosuppressant widely used as the primary drug to suppress the rejection of organ transplants. 1* FK-506, a structurally unrelated macrocycle isolated from Streptomyces tsukubaensis,2) is a potent immunosuppressant shown to be effective in humantransplant recipients at doses lower than those necessary with cyclosporin A.3) Rapamycin, originally isolated on the basis of antifungal activity,4) is structurally related to FK-506 and also shows immunosuppressive activity. 5) Cyclosporin A, FK-506, and rapamycin were found to interact with cytoplasmic proteins that possess peptidyl-prolyl cis-trans isomerase (rotamase) activity. Cyclosporin A binds and inhibits the rotamase activity of cyclophilin,6) whereas FK-506 and rapamycin interact with the FK-506 binding protein (FKBP).7) The observation that structurally unrelated immunosuppressiveagents uniquely inhibit the rotamase activity of distinct cytoplasmic proteins suggested a role for this enzymatic activity in transduction of the mitogenic signal during T cell activation.
However, 506BD, a synthetic compound which contains commonstructural elements of rapamycin and FK-506, inhibits the rotamase activity of FKBPand antagonizes the immunosuppressant activity of FK-506, yet it does not inhibit activation of T cells.8) In addition, despite their structural similarity, rapamycin and FK-506 display distinct differences in their mechanisms of inhibition of T cell activation.9'10) Cyclosporin A and FK-506 act early during T cell activation and inhibit the transcription of a limited set of early T cell activation genes, whereas rapamycin appears to alter the response of cells to cytokines. The effects of cyclosporin A and FK-506on a number of molecular events that occur during T cell activation have been described, yet it is apparent that the mechanismsof action of these immunosuppressivedrugs are only partly understood.11} DEC. 1991 Dunaimycins are 24-membered macrocyclic lactones discovered in the fermentation broths of Streptomyces diastatochromogenes AB1691Q-321 and AB1711J-452. The dunaimycins are related to, but structurally distinct from, the known actinomycete metabolites cytovaricin, oligomycin, and phthoramycin.12 '13) The discovery, taxonomy, and fermentation of the producing cultures and the isolation and elucidation of structure have been described in separate papers.14'15) In this report, the in vitro immunosuppressive activity of compounds was determined with the murine mixed lymphocyte reaction (MLR) and mixed human leukocyte cultures. In addition, the ability of dunaimycin D4S to inhibit the mitogenic response of murine splenocytes to polyclonal mitogens was assessed. The effects of exogenous interleukin 2 (IL-2), potential for binding to cyclophilin or FKBP, and interactions with immunosuppressive drugs were determined to characterize the mechanismof immunosuppression by dunaimycins. Because the dunaimycins are structurally related to the oligomycins, the ability of these compounds to inhibit the catalytic activity of Na+, K+-ATPase was also measured. Finally, the in vivo immunosuppressive activity of dunaimycin D4S and oligomycin A were compared to cyclosporin A in the murine popliteal lymph node weight gain assay.
Materials and Methods

ImmunosuppressiveAgents
The dunaimyeins were isolated at Abbott Laboratories as described elsewhere.14'15) Cyclosporin A, formulated in oil as obtained from Sandoz (Switzerland), was chromatographed on silica gel in 1.5% methanol in chloroform and crystallized.
Ascomycin was isolated from the fermentation broth of HumanMixed Leukocyte Proliferation Peripheral blood was drawn into heparin treated tubes and mononuclear cells were isolated by centrifugation over Histopaque 1077 (Sigma). Stimulator cells were suspended at 107 cells/ml in complete RPMI-1 640 medium (supplemented with 10% fetal bovine serum, 2 mMglutamine, 50 u/ml benzylpenicillin, 50 /xg/ml streptomycin, and 50 fiM 2-mercaptoethanol) and incubated with 25 /jg/ml mitomycin C at 37°C for 30 minutes. After treatment, the stimulator cells were washed three times by centrifugation in complete RPMI-1640medium. For the assay, responder and stimulator cells were suspended in 200^1 of complete RPMI-1640 medium per well. Responder cells from a single individual were present at a final concentration of 5 x 105cells/ml. A pool of stimulator cells from 3-4 individuals was used and the cells from each individual were present at a final concentration of 5 x 105 cells/ml. Test compounds were diluted in complete RPMI-1640mediumand added immediately before addition of the stimulator cells. The cultures were incubated for 96hours at 37°C in a humidified atmosphere of 5%CO2 in air. After 92hours of incubation, [rae%/-3H]thymidine (0.5^Ci/well, E.I. du Pont de Nemours & Co., Inc., U.S.A.) was added. Cultures were collected onto glass fiber filters and washed with water using a PHD harvester (Cambridge Technology, Inc., U.S.A.). The incorporated amount of [rae%/-3H]thymidine was determined by scintigraphy. The IC50 of immunosuppressive compounds was determined by linear regression analysis of the data after normalization as described for the murine MLR.
EL4 Toxicity Assay EL4 cell cultures (2 x 105 cells/ml, 200/il volume) were established in microtiter plates, and after 48-hour incubations with agents, cells were enumerated with MTTas previously described.
Mitogen Stimulation
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Spleen cells were isolated from C57BL/6mice and prepared for culture as described above. Optimal concentrations of mitogens (Sigma) were determined in separate experiments, and the concentrations used were 2 /jg/ml concanavalin A, 20 /ig/ml pokeweed mitogen, 50 /ig/ml lipopolysaccharide, or 20 jUg/ml phytohemagglutinin. The ability of agents to inhibit mitogen stimulated proliferation was assessed at concentrations that inhibited the MLRby 90%. After 48-hour incubations, uptake of [methyl-3H]-thymidine was determined as described for the MLR.
IL-2 Dependent Proliferation
The ability of agents to inhibit IL-2 dependent proliferation was assessed as follows. Mixed spleen cell cultures were established as above and exposed to immunosuppressive agents in the presence of 0, 20, 50, and 100 units of recombinant murine IL-2 (Genzyme Co., U.S.A.). After 72-hour incubations, uptake of [me//*j/-3H]thymidine was measured as described for the MLR.
Irnmunophilin Binding Sodium-Potassium Dependent ATPase DEC. 1991 The inhibitory effects of compounds on the activity of Na+, K+-ATPasewere determined in Tris buffer (50mM, pH 7.6) containing NaCl 0.1 m, KC1 15mM, MgSO4 5mM, and EDTA 2mM.19) A solution of the compound to be tested (50/A) was added to 900/il of the assay buffer containing 5mMATP, and reactions were initiated by the addition of 50fi\ of a stock solution of porcine cerebral cortex Na+, K+-ATPase (0.01 units/reaction, Grade III, Sigma). After 20-minute incubations at 37°C, 500 jxl of 10% TCAwas added to each tube to stop reactions, and inorganic phosphate was quantitated as described previously.20) To assess the type of inhibition of porcine cerebral cortex Na+, K+-ATPase by dunaimycins, enzyme reactions were established as described above. The concentrations of dunaimycin D4S ranged from 10 to 50/xm, and substrate concentrations were 1, 0.5, and 0.1 mMATP. Data were plotted as the reciprocal form of the velocity equation and a replot of l/Kmapparent versus the concentration of dunaimycin (R=0.96) was used to determine the Ki.21)
The phosphatase activity of porcine cerebral cortex Na+, K+-ATPase was measured with /7-nitrophenolphosphate as the substrate in the presence of Na+ and low concentrations of K+. The reaction buffer consisted of NaCl 100mM, KC1 2mM, MgCl2 20mM, EDTA0.2mM, and histidine 30mM, pH 7.4 . The compound to be tested was dissolved in ethanol and 50fil of the solution was added to 900/zl of buffer containing the substrate, before reactions were initiated by the addition of 50//1 (0.05units/assay) of the Na+, K+-ATPase preparation. After 20-minute incubations at 37°C, 50fil of 1.0m NaOH was added to each reaction, and absorbance was measured at 400nm.
Dunaimycin Interactions with KnownImmunosuppressants
Mixed splenocyte cultures were established and exposed to agents as described above. Preliminary experiments tested serial dilutions of each drug individually, in order to establish the 50% inhibitory concentrations for [mef/zj>/-3H]thymidine uptake, and concentrations used are indicated in the text. The interactions of immunosuppressive drugs with dunaimycin D4S were analyzed by the median-effect principle using a commerciallyavailable software package.22) Uptake of [3H]Cyclosporin A Balb/c splenocytes were isolated as described above and P388 cells were cultured as previously described.17) Splenocytes (108cells/ml) and P388 cells (1012cells/ml) were incubated with 0.1, 0.5, or 2.0/ig/ml cyclosporin A spiked with tritiated cyclosporin A (specific activity was 1.2, 0.2, and 0.06 x 106 cpm///g cyclosporin A, respectively) in the presence or absence of dunaimycin D4S (0.1, 0.5, or 2/xg/ml).
Uptake of cyclosporin A was determined with a previously described sucrose-cushion centrifugation method.23) Briefly, a 2-ml sample of each cell suspension was layered on a 1-ml cushion of 0.25m sucrose in 15-ml centrifuge tubes and centrifuged at 120 xg for 10minutes. Tubes were washed twice with minimaldisturbance of the sucrose cushion, the sucrose solution was aspirated, and the cell pellet was suspended in 150/^l of 2% Triton X-100. Radioactivity present in a 100-^1 sample of the cell suspension was determined by liquid scintillation counting.
In Vivo Popliteal Lymph Node Hyperplasia For in vivo assessment of immunosuppressive activity, Balb/c spleen cells were prepared as described above for the murine MLR and X-irradiated (2000rads). Cells were washed and resuspended in Dulbecco's phosphate-buffered saline (PBS, pH 7.2) and 50jA containing 2.5 x 106cells were injected subcutaneously on the planter surface of the rear foot of C3Hrecipient mice.24) Compoundswere dissolved in ethanol to give a final solvent concentration of 1% and diluted in 0.2% carboxymethylcellulose in PBS for intraperitoneal administration in a volume of 10ml/kg. Animals were dosed on challenge (day 0) and once daily thereafter. On day 4, the mice were killed with CO2 and the popliteal nodes from the challenged limb were dissected free and weighed. Mean weights from control uninjected mice were subtracted to correct for the baseline unstimulated normal node weight. The mean weight increase from spleen cell challenged control mice given vehicle alone was used to calculate percent inhibition of node weight increase in compound-treated mice. Cyclosporin A and FK-506 potently inhibit the human and murine MLR, but are not effective inhibitors of the constitutive proliferation of cultured T leukemia cells.25) Similarly, the dunaimycins inhibited the mitogenic response in mixed murine splenocyte or humanleukocyte cultures at ng/ml concentrations, but were relatively poor inhibitors of EL4 cell proliferation (Table 1) . In parallel determinations, the ratio of the IC5Os for inhibition of the MLRand EL4 cell proliferation by dunaimycin C2 was greater than that observed with cyclosporin A or rapamycin, but less than that of ascomycin.
With the exception of dunaimycin D2, concentrations in excess of 1 fig/ml of each dunaimycin were required to inhibit the growth of EL4 cells. Dunaimycin D4S, at a concentration that inhibited the MLRby 90%, strongly inhibited the mitogenic response stimulated by concanavalin A, pokeweed mitogen, lipopolysaccharide, or phytohemagglutinin. As shown in Table 2 , no selectivity for inhibition of B or T cell mitogens was observed for rapamycin, whereas cyclosporin A and ascomycin were less potent inhibitors of proliferation induced by the B cell mitogen lipopolysaccharide.
Cyclosporin A and ascomycin inhibit production of IL-2 by T cells, but do not alter certain responses Uptake of [3H]thymidine (cpm+ SD, n -3) by spleen cells in the presence of the MLRIC90 of agents indicated. to this cytokine.9'26) The addition of exogenous recombinant IL-2 to mixed splenocyte cultures blocks the ability of cyclosporin A or ascomycin to inhibit uptake of [mef/ry/-3H]thymidine, but has no apparent effect on the immunosuppressive activity of rapamycin or dunaimycin D4S (Fig. 1 In parallel experiments, the IC50 of unlabeled cyclosporin A for displacement of radiolabeled drug was 2 ng/ml, and unlabeled FK-506 (100 jwg/ml) totally blocked binding of[3H]benzoyl ascomycin to FKBP. The dunaimycins are structurally related to oligomycin A which interacts with the extracellular side of the Na+, K+-ATPaseat a site different from the cardiac glycosides and vanadate.27) As shown in Fig.  2 , dunaimycin D4S inhibited the ATPase activity of porcine cerebral Na+, K+-ATPase with a potency % inhibition at 50 jug/ml. IC50 value, ing/ml % inhibition at 50jug/ml. 200^g/ml, one third of the total ATPase activity remained. As shown in Table 3 , each of the dunaimycins (50/xg/ml) inhibited the ATPase activity of the enzyme, and unlike oligomycin Aalso inhibited the /?-nitrophenolphosphatase activity of the enzyme in the presence of Na+ and low concentrations of K+. Reciprocal plots of the velocity equation indicated uncompetitive inhibition of Na+, K+-ATPase by dunaimycin D4S with an apparent Ki of 38//m. In a parallel experiment, uncompetitive inhibition of porcine cerebral Na+, K+-ATPase by oligomycin A with an apparent Ki of 22jumwas observed. The IC5Os for inhibition of the MLRand EL4 cell proliferation by known inhibitors of Na+, K+-ATPase were quantitated to determine if inhibition of this enzyme was sufficient to produce the toxicity profile observed with dunaimycins. As shown in Table 4 , ouabain is a relatively poor inhibitor of both the mitogenic response in mixed splenocyte cultures or proliferation of EL4 cells. Concanamycin A, is a more potent inhibitor of both processes, but no differential toxicity was observed. However, both oligomycins A and B were potent inhibitors of the MLR and were less active in inhibiting the proliferation of EL4 cells. Mixed murine splenocyte cultures were exposed to dunaimycin D4S in the presence of cyclosporin A or ascomycin to determine if interactions between these agents occurred. From the data shown in Table  5 , it appears that combinations of cyclosporin A or ascomycin with dunaimycin D4S resulted in less immunosuppressive effects. The observed inhibition of [rae%/-3H]thymidine uptake in mixed cultures in the presence of ascomycin or cyclosporin A was less than that expected by simply adding the percent inhibition observed in the presence of each agent alone. More rigorous median-effect analysis of a Concentration of dunaimycin D4S, ng/ml. b % inhibition observed in the presence of dunaimycin D4S. c % inhibition observed in the presence of combinations of dunaimycin D4S and agent indicated. d Predicted % inhibition obtained by adding the %inhibition observed in the presence of dunaimycin D4S or the agent indicated, alone in separate cultures. for dunaimycin D4Sin combination with ascomycin, cyclosporin A, and rapamycin. å Ascomycin, à" cyclosporin A, å¡ rapamycin. Fig. 4 , uptake of [3H]cyclosporin A by cultured P388 cells was not significantly affected by the presence of dunaimycin D<
The immunosuppressant activity of the dunaimycins, as described above wi been further demonstrated in an in vivo model. Table 6 shows results from testing oligomycin A in comparison to cyclosporin A in a murine model of lymphop compounds inhibited popliteal node hyperplasia in response to allogeneic challengi in vitro effects on T cell proliferation, with ED50values of 10, 0.2 and 0.9 m; However, unlike cyclosporin A, which showed relatively little toxicity at doses in t range, both oligomycin A and dunaimycin D4S were almost uniformly fatal at dc of magnitude greater than ED50 levels. 
Discussion
The dunaimycins are newspiroketal 24-memberedmacrolide antibiotics with immunosuppressive activity. Certain representatives of the dunaimycin class inhibited the mitogenic response of mouse splenocytes or human leukocytes in mixed cultures with a potency similar to that of immunosuppressive drugs, but were relatively poor inhibitors of the proliferation of cultured EL4 cells. Dunaimycin D4S was not selective in inhibiting B or T cell activation, as no differential inhibition of the mitogenic response by lectins specific for B or T cells was observed. The in vitro mechanism of immunosuppression by the dunaimycins was apparently different from that of cyclosporin A or FK-506 because the activity of dunaimycin D4S was not antagonized by exogenous IL-2, and these compounds had no apparent affinity for immunophilins in competition binding experiments. The dunaimycins antagonized the immunosuppressive activity of cyclosporin A, ascomycin and rapamycin at percent inhibition values less than 80. However, uptake of cyclosporin A by splenocytes or a cultured tumor cell line was not altered by the presence of dunaimycin D4S, suggesting that antagonism between these agents was unrelated to effects at the level of cellular transport or competition for intracellular binding of cyclosporin A. However, competition for uptake or binding by a small subset of cells present in the unfractionated spleen cell preparations can not be ruled out. Dunaimycin D4S and oligomycin A displayed in vivo immunosuppressive activity in the murine popliteal lymph node hyperplasia model, but the therapeutic index was poor in comparison to cyclosporin A.
The dunaimycins inhibited porcine Na+, K+-ATPase and /?-nitrophenylphosphatase activities.
Uncompetitve inhibition with respect to ATP and partial inhibition at relatively high concentrations indicates that dunaimycin D4Sinteracts with the Na+, K+-pumpin a manner similar to that of oligomydin A. Oligomycin A decreases the rate of turnover of ion transport and the hydrolysis of a phosphoenzyme intermediate by blocking conformational changes in the enzyme required to complete the pumpcycle, but does not completely inhibit the enzyme.28) In the presence of Na+ plus K+, fractional inhibition increases with the ATP concentration, and with saturating ATP concentrations ( > 3 mM)maximal inhibition (64%) reported for oligomycin A (2.5 /ig/ml) is similar to results obtained in this study.29) Dunaimycin D4S was also a potent, but incomplete inhibitor of the ATPase activity. In addition, the dunaimycins inhibited the phosphatase activity of the Na+, K+-pump as assessed by hydrolysis of /7-nitrophenylphosphate in the presence of Mg2+, Na+, and low concentrations of K+.30) This activity is thought to parallel the terminal hydrolysis of enzyme bound phosphate in the final steps of the Na+, K+-ATPase reaction, and is not inhibited by oligomycin A. Instead, activating effects of oligomycin A have been reported. The stimulatory effects are not understood, but inhibition of this activity by dunaimycins suggests that these macrolides interact somewhat differently than oligomycin with the Na+, K+-pump.
Electrophysiologic and functional studies have demonstrated that human T and B lymphocytes possess voltage-gated K+ channels31~33) and that agents that block these channels (verapamil, quinine, 4-aminopyridine, and tetraethylammonium ion) inhibit mitogenesis.34) Kinetic studies indicate that 4-aminopyridine and tetraethylammonium ion interfere with early events of T cell activation, and exogenous IL-2 blocked the ability of either compound to inhibit generation of cytotoxic lymphocytes. The activity of these compoundsand the general importance of ionic fluxes for signal transduction of the mitogenic response in a number of experimental models35) has led to the suggestion that K+ channels are important in transmembrane control of the T lymphocyte activation process. The importance of K+ flux for the mitogenic response suggests that disruption of membranepotential by the dunaimycins, through inhibition of the Na+, K+-pump, could explain the in vitro selectivity of the compounds. However, no correlation between potency for inhibition of the porcine Na+, K+-ATPase and uptake of [3H]thymidine in stimulated spleen cell cultures was observed, and other inhibitors of Na+, K+-ATPasestructurally unrelated to the dunaimycins did not show preferential inhibition of the mitogenic response in comparison to inhibition of proliferation of EL4 cells. Others have questioned the specificity of the inhibitory effects of K+ channel blockers, and have suggested that the effects of these agents result from inhibition of transport of essential metabolites across cell membranes.36) Hence, it remains possible that the dunaimycins inhibit the ability of stimulated ceils to divide, rather than specifically disrupting signal transduction of mitogenic stimuli.
